JP2019502384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502384A5 JP2019502384A5 JP2018535034A JP2018535034A JP2019502384A5 JP 2019502384 A5 JP2019502384 A5 JP 2019502384A5 JP 2018535034 A JP2018535034 A JP 2018535034A JP 2018535034 A JP2018535034 A JP 2018535034A JP 2019502384 A5 JP2019502384 A5 JP 2019502384A5
- Authority
- JP
- Japan
- Prior art keywords
- configuration
- ctcs
- nuclear
- ctc
- genomic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021054561A JP2021118689A (ja) | 2016-01-06 | 2021-03-29 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
| JP2023086666A JP2023116530A (ja) | 2016-01-06 | 2023-05-26 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275659P | 2016-01-06 | 2016-01-06 | |
| US62/275,659 | 2016-01-06 | ||
| US201662344703P | 2016-06-02 | 2016-06-02 | |
| US62/344,703 | 2016-06-02 | ||
| PCT/US2017/012317 WO2017120324A1 (en) | 2016-01-06 | 2017-01-05 | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021054561A Division JP2021118689A (ja) | 2016-01-06 | 2021-03-29 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019502384A JP2019502384A (ja) | 2019-01-31 |
| JP2019502384A5 true JP2019502384A5 (https=) | 2020-02-06 |
Family
ID=59273946
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535034A Pending JP2019502384A (ja) | 2016-01-06 | 2017-01-05 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
| JP2021054561A Pending JP2021118689A (ja) | 2016-01-06 | 2021-03-29 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
| JP2023086666A Pending JP2023116530A (ja) | 2016-01-06 | 2023-05-26 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021054561A Pending JP2021118689A (ja) | 2016-01-06 | 2021-03-29 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
| JP2023086666A Pending JP2023116530A (ja) | 2016-01-06 | 2023-05-26 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190025312A1 (https=) |
| EP (1) | EP3400311A4 (https=) |
| JP (3) | JP2019502384A (https=) |
| CN (2) | CN115323054A (https=) |
| AU (2) | AU2017205443A1 (https=) |
| CA (1) | CA3010311A1 (https=) |
| EA (1) | EA201891571A1 (https=) |
| WO (1) | WO2017120324A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3045918B1 (en) | 2009-10-21 | 2017-12-06 | The Scripps Research Institute | Method of using non-rare cells to detect rare cells |
| EA201691496A1 (ru) | 2014-01-27 | 2016-12-30 | Эпик Сайенсиз, Инк. | Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток |
| EA201691682A1 (ru) | 2014-02-21 | 2017-02-28 | Эпик Сайенсиз, Инк. | Способы анализирования редких циркулирующих в крови клеток |
| US11514289B1 (en) | 2016-03-09 | 2022-11-29 | Freenome Holdings, Inc. | Generating machine learning models using genetic data |
| US11222194B2 (en) * | 2016-12-30 | 2022-01-11 | Ventana Medical Systems, Inc. | Automated system and method for creating and executing a scoring guide to assist in the analysis of tissue specimen |
| EP3431611A1 (en) | 2017-07-21 | 2019-01-23 | Menarini Silicon Biosystems S.p.A. | Improved method and kit for the generation of dna libraries for massively parallel sequencing |
| US11348661B2 (en) | 2018-05-14 | 2022-05-31 | Tempus Labs, Inc. | Predicting total nucleic acid yield and dissection boundaries for histology slides |
| US10957041B2 (en) | 2018-05-14 | 2021-03-23 | Tempus Labs, Inc. | Determining biomarkers from histopathology slide images |
| CN109060989B (zh) * | 2018-08-29 | 2021-07-30 | 重庆市肿瘤研究所 | 应用iTRAQ技术研究三阴性乳腺癌外泌体差异表达蛋白的方法 |
| CN109658981B (zh) * | 2018-12-10 | 2022-10-04 | 海南大学 | 一种单细胞测序的数据分类方法 |
| EP3991171B1 (en) * | 2019-03-26 | 2025-07-09 | Tempus AI, Inc. | Determining biomarkers from histopathology slide images |
| KR102343947B1 (ko) * | 2019-09-30 | 2021-12-27 | 주식회사 피디젠 | 환자 정보 분석을 이용한 암 재발 및 전이 모니터링 시스템을 이용한 비즈니스모델 |
| EP3965119A1 (en) * | 2020-09-04 | 2022-03-09 | Koninklijke Philips N.V. | Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices |
| CN112164420B (zh) * | 2020-09-07 | 2021-07-20 | 厦门艾德生物医药科技股份有限公司 | 一种基因组瘢痕模型的建立方法 |
| WO2022225995A1 (en) * | 2021-04-19 | 2022-10-27 | F. Hoffmann-La Roche Ag | Methods and systems for gene alteration prediction from pathology slide images |
| EP4445141A1 (en) * | 2021-12-07 | 2024-10-16 | Epic Sciences, Inc. | Enhanced characterization of breast cancer |
| JP2025505920A (ja) * | 2021-12-21 | 2025-03-05 | ファウンデーション・メディシン・インコーポレイテッド | ゲノムプロファイリングの成功を予測するための方法及びシステム |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2886923T3 (es) * | 2005-09-20 | 2021-12-21 | Menarini Silicon Biosystems Spa | Métodos y composición para generar sondas de ADN de secuencia única, marcaje de sondas de ADN y el uso de estas sondas |
| DK2981624T3 (da) | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| US20160266127A1 (en) | 2013-09-30 | 2016-09-15 | Peter Kuhn | Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients |
| CA2937051A1 (en) * | 2014-01-17 | 2015-07-23 | Ontario Institute For Cancer Research (Oicr) | Biopsy-driven genomic signature for prostate cancer prognosis |
| WO2015112999A1 (en) * | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc) |
| EA201691496A1 (ru) * | 2014-01-27 | 2016-12-30 | Эпик Сайенсиз, Инк. | Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток |
| EP3100052B1 (en) * | 2014-01-30 | 2021-03-10 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
-
2017
- 2017-01-05 US US16/068,348 patent/US20190025312A1/en not_active Abandoned
- 2017-01-05 JP JP2018535034A patent/JP2019502384A/ja active Pending
- 2017-01-05 AU AU2017205443A patent/AU2017205443A1/en not_active Abandoned
- 2017-01-05 WO PCT/US2017/012317 patent/WO2017120324A1/en not_active Ceased
- 2017-01-05 CA CA3010311A patent/CA3010311A1/en active Pending
- 2017-01-05 CN CN202210926315.3A patent/CN115323054A/zh active Pending
- 2017-01-05 EP EP17736324.9A patent/EP3400311A4/en active Pending
- 2017-01-05 EA EA201891571A patent/EA201891571A1/ru unknown
- 2017-01-05 CN CN201780015212.9A patent/CN108884494A/zh active Pending
-
2021
- 2021-03-29 JP JP2021054561A patent/JP2021118689A/ja active Pending
-
2022
- 2022-01-19 US US17/579,437 patent/US20220390451A1/en not_active Abandoned
-
2023
- 2023-04-13 AU AU2023202282A patent/AU2023202282A1/en not_active Abandoned
- 2023-05-26 JP JP2023086666A patent/JP2023116530A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502384A5 (https=) | ||
| Magen et al. | Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma | |
| Oba et al. | Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s | |
| Ding et al. | Patient-derived micro-organospheres enable clinical precision oncology | |
| Garris et al. | Dendritic cells, the T-cell-inflamed tumor microenvironment, and immunotherapy treatment response | |
| JP2018534595A5 (https=) | ||
| Tsujikawa et al. | Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis | |
| Desitter et al. | A new device for rapid isolation by size and characterization of rare circulating tumor cells | |
| Shi et al. | Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology–mainland China subset analysis of the PIONEER study | |
| Stankiewicz et al. | Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas | |
| Kadota et al. | KRAS mutation is a significant prognostic factor in early-stage lung adenocarcinoma | |
| John et al. | Characterization of lymphomas developing in immunodeficient mice implanted with primary human non–small cell lung cancer | |
| Dervovic et al. | In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer | |
| Akamatsu et al. | The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy | |
| JP2013539857A5 (https=) | ||
| Liu et al. | Characterization of primary ovarian cancer cells in different culture systems | |
| Shields et al. | Late-stage MC38 tumours recapitulate features of human colorectal cancer–implications for appropriate timepoint selection in preclinical studies | |
| JP2020522697A5 (https=) | ||
| JP2018532422A (ja) | 疾患の組織学的診断および処置方法 | |
| Awe et al. | Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups | |
| Yao et al. | Tumor cells are dislodged into the pulmonary vein during lobectomy | |
| Hu et al. | Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma: M. Hu et al. | |
| Murthy et al. | Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study | |
| Gallant et al. | Predicting therapy response in live tumor cells isolated with the flexible micro spring array device | |
| Ferro et al. | Mechanisms of tumor immunotherapy, with a focus on thoracic cancers |